Recent Advances in NSAIDs-Induced Enteropathy Therapeutics: New Options, New Challenges

Table 3

New hybrid compounds.

	Representative composition	Advantages	Stage
PPI	Esomeprazole + naproxen; Esomeprazole + aspirin; Lansoprazole + naproxen	Protection of; NSAID gastropathy	FDA approval
H2 blocker	Famotidine + ibuprofen	Protection of NSAID gastropathy	FDA approval
NO	NO releasing naproxen	Improved cardiovascular toxicity	Preclinical trial
H2S	H2S releasing naproxen	Improved cardiovascular toxicity	Preclinical trial
Phosphatidylcholine	Phosphatidylcholine-ibuprofen; Phosphatidylcholine-aspirin	Protective effect on NSAID-induced small intestinal injuries in animal study	Clinical trial
Dimethyl sulfoxide	Diclofenac in dimethyl sulfoxide	Dermal administration	FDA approval

PPI: proton pump inhibitor; NSAID: nonsteroidal anti-inflammatory drug; FDA: Food and Drug Administration.